Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 2
2009 1
2010 1
2014 1
2015 2
2016 4
2017 5
2018 8
2019 5
2020 8
2021 9
2022 3
2023 8
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Results by year

Filters applied: . Clear all
Page 1
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV; IMpower133 Study Group. Horn L, et al. N Engl J Med. 2018 Dec 6;379(23):2220-2229. doi: 10.1056/NEJMoa1809064. Epub 2018 Sep 25. N Engl J Med. 2018. PMID: 30280641 Clinical Trial.
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.
Zhou C, Tang KJ, Cho BC, Liu B, Paz-Ares L, Cheng S, Kitazono S, Thiagarajan M, Goldman JW, Sabari JK, Sanborn RE, Mansfield AS, Hung JY, Boyer M, Popat S, Mourão Dias J, Felip E, Majem M, Gumus M, Kim SW, Ono A, Xie J, Bhattacharya A, Agrawal T, Shreeve SM, Knoblauch RE, Park K, Girard N; PAPILLON Investigators. Zhou C, et al. N Engl J Med. 2023 Nov 30;389(22):2039-2051. doi: 10.1056/NEJMoa2306441. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870976 Clinical Trial.
Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer.
Mountzios G, Samantas E, Senghas K, Zervas E, Krisam J, Samitas K, Bozorgmehr F, Kuon J, Agelaki S, Baka S, Athanasiadis I, Gaissmaier L, Elshiaty M, Daniello L, Christopoulou A, Pentheroudakis G, Lianos E, Linardou H, Kriegsmann K, Kosmidis P, El Shafie R, Kriegsmann M, Psyrri A, Andreadis C, Fountzilas E, Heussel CP, Herth FJ, Winter H, Emmanouilides C, Oikonomopoulos G, Meister M, Muley T, Bischoff H, Saridaki Z, Razis E, Perdikouri EI, Stenzinger A, Boukovinas I, Reck M, Syrigos K, Thomas M, Christopoulos P. Mountzios G, et al. Among authors: bozorgmehr f. ESMO Open. 2021 Oct;6(5):100254. doi: 10.1016/j.esmoop.2021.100254. Epub 2021 Sep 1. ESMO Open. 2021. PMID: 34481329 Free PMC article.
Real-world data for precision cancer medicine-A European perspective.
Christopoulos P, Schlenk R, Kazdal D, Blasi M, Lennerz J, Shah R, Budczies J, Malek N, Fröhling S, Rosenquist R, Schirmacher P, Bozorgmehr F, Kuon J, Reck M, Thomas M, Stenzinger A. Christopoulos P, et al. Among authors: bozorgmehr f. Genes Chromosomes Cancer. 2023 Sep;62(9):557-563. doi: 10.1002/gcc.23135. Epub 2023 Mar 9. Genes Chromosomes Cancer. 2023. PMID: 36852573
Re-irradiation in locally recurrent lung cancer patients.
Schlampp I, Rieber J, Adeberg S, Bozorgmehr F, Heußel CP, Steins M, Kappes J, Hoffmann H, Welzel T, Debus J, Rieken S. Schlampp I, et al. Among authors: bozorgmehr f. Strahlenther Onkol. 2019 Aug;195(8):725-733. doi: 10.1007/s00066-019-01457-2. Epub 2019 Apr 1. Strahlenther Onkol. 2019. PMID: 30937509 English.
De Novo Versus Secondary Metastatic EGFR-Mutated Non-Small-Cell Lung Cancer.
Bozorgmehr F, Kazdal D, Chung I, Kirchner M, Magios N, Kriegsmann M, Allgäuer M, Klotz LV, Muley T, El Shafie RA, Fischer JR, Faehling M, Stenzinger A, Thomas M, Christopoulos P. Bozorgmehr F, et al. Front Oncol. 2021 Apr 9;11:640048. doi: 10.3389/fonc.2021.640048. eCollection 2021. Front Oncol. 2021. PMID: 33898315 Free PMC article.
Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer.
Magios N, Bozorgmehr F, Volckmar AL, Kazdal D, Kirchner M, Herth FJ, Heussel CP, Eichhorn F, Meister M, Muley T, Elshafie RA, Fischer JR, Faehling M, Kriegsmann M, Schirmacher P, Bischoff H, Stenzinger A, Thomas M, Christopoulos P. Magios N, et al. Among authors: bozorgmehr f. Ther Adv Med Oncol. 2021 Mar 24;13:1758835921996509. doi: 10.1177/1758835921996509. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 34408792 Free PMC article.
Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors.
Rheinheimer S, Heussel CP, Mayer P, Gaissmaier L, Bozorgmehr F, Winter H, Herth FJ, Muley T, Liersch S, Bischoff H, Kriegsmann M, El Shafie RA, Stenzinger A, Thomas M, Kauczor HU, Christopoulos P. Rheinheimer S, et al. Among authors: bozorgmehr f. Cancers (Basel). 2020 Apr 23;12(4):1046. doi: 10.3390/cancers12041046. Cancers (Basel). 2020. PMID: 32340408 Free PMC article.
50 results